Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

Microneedling may not significantly help those who don't respond to topical minoxidil, and some users suggest trying oral treatments like oral minoxidil or finasteride. Concerns about scarring and side effects are noted, with mixed experiences reported.

Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.

The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.

Hair loss discussion involves minoxidil, finasteride, and RU58841. Minoxidil non-responders may see results after adding stemoxydine due to increased enzyme presence.

A monoclonal antibody clinical trial for potential hair loss treatments in Victoria, Australia and the discussion of their efficacy. People shared information about similar drugs already on the market, speculated about potential side effects, and discussed how to spread the word about the trial.

The user is considering using tretinoin with topical finasteride due to poor absorption and side effects from oral finasteride. They are also contemplating switching to topical dutasteride, while others suggest trying oral minoxidil or lower oral doses.

KX-826 (Pyrilutamide) 0.5% and 1.0% solutions showed promising results in increasing hair count for male androgenetic alopecia, with the 0.5% dose slightly outperforming the 1% dose. The treatment was well-tolerated with no sexual side effects, but skepticism remains due to past inconsistencies in trial results.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

The user is considering liposomal minoxidil due to non-response and side effects from other treatments. They are exploring tretinoin with topical minoxidil as an alternative.

Kintor's Phase II U.S. trials for pyrilutamide and the process of pharmaceutical drugs coming to market, with a reply from someone who has just ordered 500mg of Pyrilutamide to start their own phase trials.

The user is concerned about the quick prescription process for hair loss treatments like Minoxidil and Finasteride through HIMs, questioning the lack of a thorough evaluation. Another user reassures that such practices are common, emphasizing the effectiveness and low risk of these treatments, and suggests monitoring personal response to the medication.

The user reported significant hair regrowth after seven months using topical minoxidil 5% combined with 0.1% finasteride and weekly micro needling. The community responded positively, noting visible improvement and discussing the effectiveness of topical versus oral finasteride.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

The conversation discusses how applying topical tretinoin for 5 days can convert 43% of individuals who initially do not respond to minoxidil into responders, enhancing the effect of minoxidil on hair growth. Specific treatments mentioned are minoxidil and tretinoin.

A 20-year-old user experienced worsening hair loss despite using various treatments including topical and oral minoxidil, finasteride, and dutasteride. Other users suggested additional treatments like JAK inhibitors, RU58841, and lifestyle changes, but the user remains skeptical and frustrated.

A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.

A user expressed frustration with hair loss treatments, including finasteride, minoxidil with micro-needling, and RU58841, which all failed to stop hair thinning and miniaturization. Suggestions from others included accepting baldness, considering hair systems, and continuing prescribed antidepressants for depression.

The conversation is about using PTD-DBM Peptide from Infiniwell for hair loss. The original poster is seeking feedback on its effectiveness.

The user experienced no response to 5 mg oral minoxidil after 6 months, with no hair regrowth or shedding. Suggestions included trying topical finasteride, dermastamping, and addressing DHT, while some users noted that factors like aspirin or Accutane might affect results.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

Microneedling with minoxidil significantly boosts hair growth, even for non-responders to minoxidil alone. The routine includes a 1.5mm dermaroller weekly and minoxidil twice daily, with some users adding finasteride and tretinoin.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

The conversation discusses the effectiveness of using finasteride alone versus combining it with minoxidil, ketoconazole, and microneedling for hair loss treatment. It also touches on the affordability and accessibility of hair transplants, with differing opinions on the financial feasibility of such procedures.

People are discussing using tretinoin gel with minoxidil to improve hair growth, especially for those who didn't respond to minoxidil alone. They apply a mix of tretinoin gel and minoxidil to the scalp, which is said to be more effective than minoxidil by itself.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

The conversation discusses concerns about the effectiveness of finasteride for hair loss. The user is worried about being a non-responder to the treatment.